IJCRR - Vol 05 Issue 16, August, 2013
EFFICACY AND SAFETY OF ORAL TRIPLE DRUG COMBINATION (VOGLIBOSE, GLIMEPIRIDE AND METFORMIN) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS
Author: C. Rao, A. A. Faruqui
The prevalence of type 2 diabetes across the world has been described as a global pandemic. Despite the introduction of new agents, efforts for better management of diabetes are disappointing and the control of blood glucose level remains unsatisfactory. When antidiabetic therapy is initiated, it is now recommended that the selection of agents should be directed towards both fasting as well as postprandial hyperglycaemia. Material and method: This study was a post marketing surveillance (PMS) non-randomized, open, non-comparative, mono centric study. The drug administered was a fixed dose combination of Voglibose 0.2mg, Glimepiride 1/2mg and Metformin 500mg SR, 20 type 2 diabetic patients were given fixed dose combination twice daily with major meals for 3 months. Observation: Baseline value was recorded for glycated haemoglobin (HbA1c), fasting blood glucose and post prandial blood glucose level. There was significant decrease in glycated haemoglobin value (8.86 ± 0.7111 gm/dl vs. 8.0 ± 0.66 gm/dl), fasting (137±17.64 mg/dl vs. 116.8 ± 6.129 mg/dl, P < 0.0001) and post prandial blood glucose level ((237.8 ± 59.22 mg/dl vs.173.4 ± 27.6 P < 0.0004) after 3 months of treatment. The combination was found to be effective in controlling both fasting and post prandial glucose level and was well tolerated. Investigator commented that the use of triple drug combination is a good option in the management of type 2 diabetes which controls both fasting as well as post prandial blood glucose. Conclusion: The triple drug fixed dose combination of Voglibose, Glimepiride and Metformin significantly decreased the HbA1c value, fasting plasma glucose level and post prandial glucose level at the end of the treatment.
Keywords: HbA1c, Fasting Plasma Glucose, Post Prandial Blood Glucose, PMS
C. Rao, A. A. Faruqui. EFFICACY AND SAFETY OF ORAL TRIPLE DRUG COMBINATION (VOGLIBOSE, GLIMEPIRIDE AND METFORMIN) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS International Journal of Current Research and Review. Vol 05 Issue 16, August, 20-26
1. Nathan DM, Kitrick C, Larkin M, Schaffran R, Singer DE. Glycemic control in diabetes mellitus: have changes in therapy made a difference? Am J Med 1996;100:157-63.
2. A. Ceriello. The glucose triad and its role in comprehensive glycaemic control: current status, future management: Int J Clin Pract, November 2010; 64(12): 1705–1711.
3. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2008; 31(Suppl. 1): S12–54.
4. Canadian Diabetes Association. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32(Suppl. 1): S1–201.
5. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136
6. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481–9
7. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J. Guideline for Management of Postmeal Glucose. Brussels: International Diabetes Federation, 2007.
8. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995;18:1510-8.
9. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000;108 (suppl 6a):15S-22S.
10. Ovalle F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract 1998;4:146-7
11. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in EuropeLancet 1999; 354: 617–621.
12. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria, Arch. Intern. Med. 2001; 161 397–405.
13. F. Cavalot, A. Petrelli, M. Traversa, K. Bonomo, E. Fiora, M. Conti, et al., Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study, J. Clin. Endocrinol. Metab. 91 (2006) 813–819.
14. Kuo-Liong Chien a,b, Bai-Chin Lee b, HungJu Lin b, Hsiu-Ching Hsu b, Ming-Fong Chen; Association of fasting and post-prandial hyperglycemia on the risk of cardiovascular and all-cause death among non-diabetic Chinese: Diabetes research and clinical practice 2009; 83:e4 7– e50
15. S. Yamagishi, K. Nakamura, M. Takeuchi, Inhibition of postprandial hyperglycaemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome, Med. Hypotheses 65 (2005) 152– 154.